Seminars in Hematology
Volume 46, Issue 2 , Pages 176-189 , April 2009

Management of Complications in Multiple Myeloma

  • Evangelos Terpos

      Affiliations

    • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    • Corresponding Author InformationAddress correspondence to Evangelos Terpos, Department of Clinical Therapeutics, University of Athens School of Medicine, 5 Marathonomahon St, Drosia, 14572, Athens, Greece
    • ,
  • M. Teresa Cibeira

      Affiliations

    • Institute of Hematology and Oncology, Hematology Department, Postgraduate School of Hematology Farreras Valentí, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Joan Blade

      Affiliations

    • Institute of Hematology and Oncology, Hematology Department, Postgraduate School of Hematology Farreras Valentí, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Heinz Ludwig

      Affiliations

    • Department of Medicine I and Medical Oncology, Wilhelminenspital, Vienna, Austria

References 

  1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  2. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16:1223–1231
  3. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(suppl 4):14–27
  4. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581–11586
  5. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97:3349–3353
  6. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534–3540
  7. McDonald RJ, Trout AT, Gray LA, Dispenzieri A, Thielen KR, Kallmes DF. Vertebroplasty in multiple myeloma: outcomes in a large patient series. AJNR Am J Neuroradiol. 2008;29:642–648
  8. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol. 2003;123:758–769
  9. Terpos E, Rahemtulla A. Bisphosphonate treatment for multiple myeloma. Drugs Today. 2004;40:29–40
  10. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9:1397–1402
  11. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20:2353–2359
  12. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377–387
  13. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735–1744
  14. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139:101–111
  15. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10:52–62
  16. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968–971
  17. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620–623
  18. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma (MM) treated with zoledronic acid. Ann Oncol. 2009;20:117–120
  19. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904–5909
  20. Anderson K, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, et al. National Comprehensive Cancer Network (NCCN) Multiple myeloma (Clinical practice guidelines in oncology). J Natl Compr Cancer Netw. 2007;5:118–147
  21. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464–2472
  22. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047–1053
  23. Harousseau JL, Greil R, Kloke O. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005;16(suppl 1):i45–i47
  24. Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007;82:516–517
  25. Grossman SA. Undertreatment of cancer pain: barriers and remedies. Support Care Cancer. 1993;1:74–78
  26. World Health Organization. Cancer pain relief and palliative care: report of a WHO expert panel (WHO Technical Report 804). Geneva: WHO; 1990;
  27. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol. 2002;20:2382–2387
  28. Cherny NI, Portenoy RK. The management of cancer pain. CA Cancer J Clin. 1994;44:263–303
  29. Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol. 2006;77:378–386
  30. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992;82:648–653
  31. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987–1994
  32. Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, et al. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol. 1990;44:186–189
  33. Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest. 1993;91:251–256
  34. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1:CD005033
  35. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172–179
  36. Ludwig H. Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol. 2006;43(suppl 6):S13–S17
  37. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol. 1995;70:313–318
  38. Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma (A prospective, randomized, placebo-controlled, double-blind trial). Arch Intern Med. 1995;155:2069–2074
  39. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995;86:4446–4453
  40. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Epoetin Beta Hematology Study Group: randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486–2494
  41. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol. 2003;122:386–393
  42. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Darbepoetin Alfa 20000161 Study efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394–403
  43. Musto P, Falcone A, D'Arena G, Scalzulli PR, Matera R, Minervini MM, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol. 1997;58:314–319
  44. Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040–1050
  45. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol. 2005;129:206–209
  46. Katodritou E, Zervas K, Terpos E, Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol. 2008;142:3–10
  47. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895
  48. Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2006;117:162–167
  49. Katodritou E, Verrou E, Hadjiaggelidou C, Gastari V, Laschos K, Kontovinis L, et al. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol. 2008;83:697–701
  50. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714
  51. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079–2080
  52. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma (Presenting features and predictors of outcome in a series of 94 patients). Arch Intern Med. 1998;158:1889–1893
  53. Dimopoulos MA, Kastritis E, Rosiñol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–1493
  54. Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med. 1994;124:484–488
  55. Torra R, Bladé J, Cases A, López-Pedret J, Montserrat E, Rozman C, et al. Patients with multiple myeloma and renal failure requiring long-term dialysis: presenting features, response to therapy and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–859
  56. Mezzano SA, Barria M, Droguett MA, Burgos ME, Ardiles LG, Flores C, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60:1366–1377
  57. Takase O, Hirahashi J, Takayanagi A, Chikaraishi A, Marumo T, Ozawa Y, et al. Gene transfer of truncated I kappa B alpha prevents tubulointerstitial injury. Kidney Int. 2003;63:501–513
  58. Bladé J, Lust JA, Kyle RA. Immunoglobulin D myeloma: presenting features, response to therapy, and survival in a series of 53 patients. J Clin Oncol. 1994;12:2398–2404
  59. Randall RE, Williamson WC, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light-chain deposition. Am J Med. 1976;60:293–299
  60. Dhodapkar MV, Merlini G, Solomon A. Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am. 1997;11:89–110
  61. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high-dose dexamethasone containing regimens and impact of novel agents. Haematologica. 2007;92:546–549
  62. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplantation in multiple myeloma with renal failure. Br J Haematol. 2001;114:822–829
  63. San Miguel JF, Lahuerta JJ, García-Sanz R, Alegre A, Bladé J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. Hematol J. 2000;1:28–36
  64. Lee CK, Zangari M, Barlogie B. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823–828
  65. San Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 trial. Leukemia. 2008;22:842–849
  66. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–2606
  67. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92:1411–1414
  68. Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–3977
  69. Bladé J, Rosiñol L. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1231–1246
  70. Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995;48:260–266
  71. Oken MM, Pomeroy C, Weisdorf D. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100:624–628
  72. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917
  73. Daragon A, Humez C, Michot C, Le Loet X, Grosbois B, Pouyol F, et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study (Groupe d'Etudes et de Recherches sur le Myelome (GERM)). Eur J Med. 1993;2:449–452
  74. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma (Finnish Leukaemia Group). Lancet. 1992;340:1049–1052
  75. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035–1043
  76. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial (Danish-Swedish co-operative study group). Br J Haematol. 1998;101:280–286
  77. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma (Myeloma Aredia Study Group). N Engl J Med. 1996;334:488–493
  78. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events (Myeloma Aredia Study Group). J Clin Oncol. 1998;16:593–602
  79. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191–1200
  80. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia. 2007;21:1875–1884

 Supported in part by a Spanish Grant from Instituto Carlos III RD06/0020/0005 and the Austrian Forum Against Cancer.

PII: S0037-1963(09)00006-7

doi: 10.1053/j.seminhematol.2009.01.005

Seminars in Hematology
Volume 46, Issue 2 , Pages 176-189 , April 2009

Article Tools

* Image Usage & Resolution